Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16220840 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15825878 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL16220851 | 1.00 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL16220687 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15825425 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30255087 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30254920 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15825429 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15835832 | 0.95 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL15825307 | 0.93 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.